[1] 冯力民, 边茜. 诺舒阻抗控制子宫内膜切除术的临床应用现状. 武警医学, 2016, 27: 541-544.
[2] 韦利英, 赵仁峰, 李雪, 等. 诺舒阻抗子宫内膜切除系统治疗月经过多151例分析. 中国妇产科临床杂志, 2016, 17: 132-135.
[3] Lee MMH, Khadra M. Predictive Factors Affecting the Success of a NovaSure Endometrial Ablation. Hong Kong J Gynaecol Obstet Midwifery, 2013, 13: 108-113.
[4] 李丽, 李红芳, 易为, 等. 女性肝硬化患者性激素水平变化的初步探讨. 临床肝胆病杂志, 2017, 33: 72-75.
[5] 刘军, 王玲, 刘敏, 等. 肝硬化患者合并非妊娠异常子宫出血的诊断和治疗. 中华肝脏病杂志, 2011, 19: 52-54.
[6] Luo X, Lim CE, Li L, et al. Hysteroscopic appearance of endometrial cavity after microwave endometrial ablation. J Minim Invasive Gynecol, 2010, 17: 30 -36.
[7] Gimpelson RJ. Ten-year literature review of global endometrial ablation with the NovaSure® device. Int J Womens Health,2014, 6: 269-280.
[8] Herman MC, van den Brink MJ, Geomini PM, et al. Levonorgestrel releasing intrauterine system (Mirena) versus endometrial ablation (Novasure) in women with heavy menstrual bleeding: a multicentre randomized controlled trial. BMC Womens Health, 2013, 13: 32.
[9] 刘青, 张华, 刘继娟, 等. 诺舒阻抗控制子宫内膜切除治疗肝病合并异常子宫出血30 例. 中国微创外科杂志, 2014, 14: 304-307.
[10] Fulop T, Rákóczi I, Barna I. NovaSure impedance controlled endometrial ablation: long-term follow-up results. J Minim Invasive Gynecol, 2007, 14: 85-90.
[11] Campbell P, Monaghan C, Parker M. NovaSure endometrial ablation: a review of 400 cases. Gynecol Surg, 2012,9: 73-76.
[12] 黄伟容, 吴玉英, 赵仁峰. 第二代子宫内膜去除术诺舒治疗尿毒症合并月经过多的临床分析. 实用医学杂志, 2015, 31: 3069-3071.
[13] Krogh RA, Lauszus FF, Guttorm E, et al. Surgery and cancer after endometrial resection. Long-term follow-up on menstrual bleeding and hormone treatment by questionnaire and registry. Arch Gynecol Obstet, 2009, 280: 911-916.
[14] 李秀兰, 刘青, 冉冉, 等. 473例肝病患者异常子宫出血的病因分析. 北京医学, 2017, 39: 924-927.
[15] 马宁, 夏恩兰, 赵玉婷, 等. 第二代子宫内膜去除术诺舒临床应用70例分析. 国际妇产科学杂志, 2014, 41: 526-530. |
